Saturday, September 14, 2019, Houston, Texas, 6:15 AM – 7:45 AM

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia

An Independent Satellite Symposium During the Society of Hematologic Oncology 2019 Annual Meeting

Hilton Americas-Houston
1600 Lamar Street
Houston, Texas 77010
Hotel Phone: (713) 739-8000

5:45 AM – 6:15 AM — Registration
6:15 AM – 7:45 AM — Educational Breakfast Program

Meeting Room
Grand Ballroom G-L (fourth floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Jennifer R Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

William G Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jennifer Woyach, MD
Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive
Cancer Center
Columbus, Ohio

Christopher R Flowers, MD, MS
Professor, Hematology and Medical Oncology
Director, Emory Lymphoma Program
Scientific Director, Winship Research Informatics
Winship Cancer Institute
Atlanta, Georgia

Not an official program of the SOHO 2019 Annual Meeting. Not sponsored or endorsed by the Society of Hematologic Oncology.

Meeting Agenda and Format

Prior to this event, the faculty members and 3 other hematologic oncology investigators will be asked to complete a case-based Consensus or Controversy (CoC) survey designed to document their usual approaches to a variety of clinical scenarios and management questions. During the program, the responses to specific CoC questions will be graphically displayed for the audience. Short didactic presentations will also be included to provide a formal review of available data and ongoing trials.

MODULE 1: Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Dr Woyach

  • Identification and clinical relevance of existing and emerging biomarkers (del[17p], IGHV mutations, TP53 mutations, complex karyotype, minimal residual disease [MRD], et cetera) and implications, if any, for clinical decision-making in the first-line setting
  • Key efficacy and safety findings from the Phase III ECOG-E1912 trial comparing ibrutinib/rituximab to FCR (fludarabine/cyclophosphamide/rituximab) for young, fit patients with treatment-naïve CLL
  • Outcomes from the Phase III Alliance A041202 trial evaluating ibrutinib versus ibrutinib/rituximab versus bendamustine/rituximab (BR) for older patients with previously untreated CLL
  • Results from the Phase III iLLUMINATE trial comparing ibrutinib/obinutuzumab to chlorambucil/obinutuzumab for treatment-naïve CLL; recent FDA approval of ibrutinib/obinutuzumab and patient selection for its use
  • Design, eligibility requirements and primary and secondary outcomes achieved in the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical implications of the recent FDA approval of this regimen

MODULE 2: Existing and Recently Approved Approaches for Patients with Relapsed/Refractory (R/R) CLL — Dr Flowers

  • Rationale for repeat biomarker assessment in patients with progressive CLL; current applicability, if any, to treatment decision-making
  • Long-term follow-up from the Phase III MURANO trial comparing venetoclax/rituximab to BR for R/R CLL
  • Frequency, spectrum and grade of toxicities observed with venetoclax/rituximab versus BR in the MURANO study
  • Incidence of tumor lysis syndrome (TLS) observed in patients with CLL treated with venetoclax; indications for and implementation of prophylactic measures against TLS
  • Design, eligibility criteria and key efficacy and safety outcomes from the Phase III DUO trial evaluating duvelisib versus ofatumumab for R/R CLL; FDA approval of duvelisib and optimal role of PI3 kinase inhibition in patients with R/R CLL

MODULE 3: Acalabrutinib and Other Promising Strategies Under Investigation — Dr Brown

  • Mechanistic and pharmacodynamic similarities and differences among ibrutinib, acalabrutinib and other developmental BTK inhibitors
  • Key findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL
  • Design, eligibility criteria and estimated completion date for the ongoing Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for high-risk R/R disease
  • Early activity and safety experience with acalabrutinib for treatment-naïve disease; emerging results from the Phase III ELEVATE-TN trial comparing obinutuzumab/chlorambucil, acalabrutinib/obinutuzumab and acalabrutinib for patients with previously untreated CLL
  • Frequency of side effects (eg, atrial fibrillation, headache, infections) observed in patients with CLL receiving acalabrutinib; optimal preventative, supportive and dose-reduction strategies
  • Ongoing investigation of other novel approaches in CLL (eg, chimeric antigen receptor T-cell therapy, zanubrutinib, ublituximab, umbralisib, dinaciclib)

MODULE 4: Available Data with and Potential Role of Novel Combination Approaches — Dr Wierda

  • Efficacy findings associated with the use of novel combination approaches for patients with previously untreated and R/R CLL (eg, ibrutinib/venetoclax, ibrutinib/obinutuzumab/venetoclax, acalabrutinib/obinutuzumab)
  • Rates of MRD negativity and use of MRD assessment to guide discontinuation of treatment with novel combination approaches; CAPTIVATE and CLARITY trials as models
  • Frequency and severity of adverse events observed in studies of novel targeted combinations
  • Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL (eg, FLAIR, CLL13 [GAIA], CLL3011 [GLOW])

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Recall the incidence, prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that may be associated with a diagnosis of CLL, and use this information to develop evidence-based testing algorithms in general oncology practice.
  • Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status.
  • Evaluate available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch treatment algorithms.
  • Assess the recent FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current treatment decision-making.
  • Consider published research data, prior therapeutic exposure and the results of biomarker analyses when developing management strategies for patients with CLL who experience disease progression on first and subsequent lines of therapy.
  • Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating the use of chemotherapy-free combinations involving novel targeted agents in the management of newly diagnosed and progressive CLL, and identify patients who may be suitable candidates for these approaches outside or as part of an ongoing research study.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of CLL.
  • Recall available and emerging data with other investigational agents, combinations and strategies currently in Phase III testing for CLL, and where applicable, refer eligible patients for trial participation or expanded access programs.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Hilton Americas-Houston
1600 Lamar Street
Houston, Texas 77010
Hotel Phone: (713) 739-8000

Meeting Room
Grand Ballroom G-L (fourth floor)

Hilton Americas-Houston is the host hotel for the Society of Hematologic Oncology’s seventh annual meeting.


This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.